PDPHF (Egetis Therapeutics AB) GF Score: 24/100 (As of Jun. 25, 2026) — Near Median


PDPHF Egetis Therapeutics AB PDPHF
24 GF Score
Price $0.64
GF Value $0.66
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB GF Score?

Egetis Therapeutics AB PDPHF 24 GF Score is 24 as of Jun. 25, 2026, which is 8% below its 10-year median of 26.00. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.66 (Fairly Valued). The stock has 5 warning signs investors should review.

Egetis Therapeutics AB has the GF Score of 24, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 1/10
3. Growth Rank : 7/10
4. GF Value Rank : 7/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Egetis Therapeutics AB might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Egetis Therapeutics AB  (OTCPK:PDPHF) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Egetis Therapeutics AB GF Score Related Terms

PDPHF vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egetis Therapeutics AB GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's GF Score distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's GF Score falls into.


PDPHF
24GF Score
Egetis Therapeutics AB PDPHF
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 24 mean?
Egetis Therapeutics AB (PDPHF) has a GF Score of 24 as of Jun. 25, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Egetis Therapeutics AB and its competitors. This is near median its historical median of 26.00. Over the past decade, Egetis Therapeutics AB's GF Score has ranged from 26.00 to 26.00.
Is Egetis Therapeutics AB's GF Score too high?
Egetis Therapeutics AB's current GF Score of 24 is near median its 10-year median of 26.00. Over the past 10 years, this metric has ranged from a low of 26.00 to a high of 26.00. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's GF Score compare to VRTX and REGN?
Egetis Therapeutics AB's GF Score of 24 can be compared against companies in the Biotechnology industry. Historically, Egetis Therapeutics AB's own GF Score has ranged from 26.00 to 26.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current GF Score is 24, which is near median its own 10-year median of 26.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.66, compared to a current price of $0.64 — trading 3.7% below its estimated fair value. The current GF Score is 24, which is near median its 10-year median of 26.00. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current GF Score is 24 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued. The current stock price of $0.64 is trading 3.7% below its estimated GF Value™ of $0.66. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for PDPHF:

  • GF Score: 24 (near median its 10-year median of 26.00)
  • GF Value™: $0.66 vs. price of $0.64 (3.7% below fair value)
  • GF Score™: 24/100 with 5 warning signs

No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score

Get the complete analysis for PDPHF

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price
$0.66
GF Value